In a regulatory filing, Twist Bioscience (TWST) CEO Emily Leproust disclosed the sale of 31,348 common shares of the company on October 6 a a price of $32.187 per share, or a total consideration of $1.01M.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Twist Bioscience price target lowered to $40 from $45 at Barclays
- Cathie Wood Loads Up on Klarna, Synopsys, and Rubrik, Trims Shopify and Roblox Stocks
- Cathie Wood’s ARK Investment buys 221.7K shares of Twist Bioscience today
- PRME, TWST, TEM: Cathie Wood Pours $1.9M Into Biotech, Cuts Stake in AI Stock
- Cathie Wood’s ARK Investment buys 47.7K shares of Twist Bioscience today